Background: The use of monoclonal antibodies to deliver radioactive isotopes directly to tumor cells has become a promising
Introduction
Despite advances in therapy, only about 20%-30% of patients with acute myelogenous leukemia (AML) activation, thereby initiating a number of biologically important effects that disrupt the integrity of the cell membrane. Cells with antibody and complement on their surfaces may also be engulfed, or opsonized, by macrophages. Another important mechanism for tumor cell killing by native MAbs is antibody-dependent cell-mediated cytotoxicity (ADCC), in which an effector cell expressing an Fc receptor binds to a cell-bound MAb and is triggered to kill the target cell. Monocytes, macrophages, natural killer cells, and neutrophils can affect antibody-dependent cell-mediated cytotoxicity.
Chimeric and humanized antibodies have been constructed to overcome the weak antitumor activity and the immunogenicity of many murine MAbs. These antibodies retain the binding specificity of the original rodent antibody determined by the variable region but can potentially activate the human immune system through their human constant region. Clinical trials have demonstrated that both rituximab, a chimeric anti-CD20 MAb, and Campath-1H, a humanized anti-CD52 MAb, have activity against chronic lymphocytic leukemia. 3, 4 However, the activity of native antibodies in acute leukemias is more limited. The humanized anti-CD33 MAb HuM195 has been shown to eliminate minimal residual disease detectable by reverse transcription-polymerase chain reaction (RT-PCR) in patients with acute promyelocytic leukemia (APL) 5 and to produce rare complete remissions in patient with relapsed or refractory AML, but only in patients with low leukemic burdens. [6] [7] [8] In order to increase the antitumor effects of native antibodies, drugs and bacterial toxins have been conjugated to MAbs. For example, gemtuzumab ozogamicin consists of a humanized anti-CD33 antibody linked to calicheamicin, a potent tumor antibiotic. Gemtuzumab ozogamicin has produced remissions in 30% of carefully selected patients with relapsed AML. 9 BL22 is a recombinant immunotoxin consisting of the variable domain of an anti-CD22 antibody fused to a fragment of Pseudomonas exotoxin. In a recent trial, BL22 resulted in an 81% response rate in patients with hairy cell leukemia refractory to cladribine.
10 Table 1 lists the labeled and unlabeled antibodies that have been used to treat leukemias in recent trials.
In an alternative approach, antibodies can be used to target radioisotopes directly to sites of disease in order to increase the antitumor effects of native MAbs. This article reviews the role of radioimmunotherapy with both α-particles and β-particles in the treatment of leukemia.
Isotope Selection
When selecting a radioisotope for clinical use, the characteristics of the isotope must be considered, CD25 ATL Delivers β-particle emitter CLL = chronic lymphocytic leukemia PLL = prolymphocytic leukemia AML = acute myelogenous leukemia MDS = myelodysplastic syndrome APL = acute promyelocytic leukemia HCL = hairy cell leukemia CML = chronic myelogenous leukemia ALL = acute lymphoblastic leukemia ATL = adult T-cell leukemia ADCC = antibody-dependent cellular cytotoxicity CMC = complement-mediated cytotoxicity including its half-life and the type of particle(s) it emits. The physical properties of several commonly used isotopes for the clinical radioimmunotherapy of leukemia are summarized in Table 2 .
β-Particles have a relatively long range (0.8-5 mm) and low linear energy transfer (approximately 0.2 keV/µm). This long range results in the delivery of radiation not only to the target cell but also to surrounding cells. Thus, cross-firing β-particles create a field effect, potentially irradiating antigen-negative tumor cells. Normal bystander cells, however, may be killed as well. The physical properties of β-particleemitting radioimmunoconjugates make them useful in treating bulky disease and in selectively irradiating the entire bone marrow before hematopoietic stem cell transplantation. β-particle emitters, however, are less well-suited to the killing of single cells and to the treatment of small-volume, minimal residual, or micrometastatic disease.
Most clinical studies have used 131 I, a long-lived β-particle emitter. The emissions from 131 I allow dosimetry studies to be performed easily, but treatment at high doses requires patient isolation and can result in radiation exposure to hospital staff. More recently, the use of radiometals, such as 90 Y and 188 Re, has been investigated. 90 Y is a pure β-emitter; its lack of γ-emissions allows outpatient administration of high doses. Therapy with 90 α-Particles are helium nuclei emitted from the decay of radioisotopes. There are approximately 100 radioisotopes that decay with α-particle emissions. Compared with β-particles, α-particles have a shorter range (50-80 µm) and a higher linear energy transfer (approximately 100 keV/µm). 24 As few as one or two α-particles traversing the nucleus can destroy a target cell. Therefore, because of the short range of α-particles, radioimmunotherapy with α-emitters should result in less nonspecific toxicity to normal bystander cells and in more efficient singlecell killing than β-emitting constructs. This potential for specific antitumor effects makes targeted α-particle therapy an attractive approach for the treatment of cytoreduced or minimal residual disease.
Radioimmunotherapy With β-Particle Emitters
Radiolabeled Anti-CD33 Antibodies CD33 is a 67-kD cell surface glycoprotein found on most myeloid leukemia cells and on committed myelomonocytic and erythroid progenitor cells. It is not found on lymphoid or nonhematopoietic cells. 25, 26 Three anti-CD33 MAbs have been used in the radioimmunotherapy of myeloid leukemias: M195, HuM195, and p67. M195 is a murine monoclonal IgG2a antibody that is derived from a mouse immunized with live human leukemic myeloblasts. 27 HuM195 is a humanized antibody constructed by grafting the complementarity-determining region of M195 onto the constant region and variable framework of a human IgG1 antibody.
28 HuM195 differs from the murine M195 in two important ways. First, HuM195 can mediate the killing of leukemia cells in vitro by human peripheral blood mononuclear cells, whereas M195 cannot. 29, 30 Second, while significant numbers of patients treated with murine M195 develop human antimouse antibodies that adversely affect the pharmacokinetics of the antibody and preclude re-treatment with it, patients treated with HuM195 do not develop significant immune responses. 6, 7, 11, 12 The third anti-CD33 MAb formerly in clinical use for radioimmunotherapy is p67, a murine IgG1 antibody. Twenty-two of the 24 patients had reductions in their leukemic burden. Gamma camera imaging showed targeting to areas of leukemic involvement, including the marrow of the vertebrae, pelvis, and long bones, as well as the liver and spleen. The isotope was retained at these sites for at least 3 days. Profound myelosuppres- Subsequently, myeloablative doses of 131 I-M195 and 131 I-HuM195 (120 to 380 mCi) were studied in combination with busulfan (16 mg/kg) and cyclophosphamide (90 or 120 mg/kg) as a preparative regimen before allogeneic bone marrow transplantation. Thirty patients received the treatment on one of three protocols. Sixteen patients had refractory or relapsed AML, and 14 had relapsed, accelerated, or myeloblastic phase CML. Nineteen patients received 131 I-M195, and 11 received 131 I-HuM195. Twenty-eight of the 30 patients achieved complete remission. Three of the 16 patients with AML remain in remission between 4.5 and 8 years posttransplant. No significant toxicities were attributable to the addition of the radiolabeled antibody to the conditioning regimen, and engraftment was not delayed. 12 Taken together, these studies indicate that 131 I-M195 and 131 I-HuM195 have activity in myeloid leukemias and can be used safely in conjunction with standard chemotherapeutic agents as a conditioning regimen for hematopoietic stem cell transplantation. This approach potentially allows for intensification of antileukemic therapy before transplant.
The ability of nonmyeloablative doses of 131 I-M195 to eliminate minimal residual disease in patients with relapsed APL after induction with all-trans retinoic acid was studied. Six of 7 patients had minimal residual disease detectable by RT-PCR after induction with retinoic acid. The patients then received two doses of 131 I-M195 (50 or 70 mCi/m 2 ). Two of the 6 patients transiently became RT-PCR negative. The median disease-free survival was 8 months. This compared favorably to the 3-month median disease-free survival seen in patients with relapsed APL treated solely with all-trans retinoic acid. While 131 I-M195 had activity against minimal residual disease, this therapy was limited by myelosuppression in all patients and by the formation of human antimouse antibodies in 5 patients.
12,13
131 I-p67 -In a phase I study at the Fred Hutchinson Cancer Research Center (FHCRC), 131 I-p67 was investigated in patients with advanced AML. Nine patients received a tracer dose of 131 I-p67, and the biodistribution and estimated radiation absorbed dose to various organs were determined. The half-life of 131 Ip67 in the marrow was 9 to 41 hours. This short halflife presumably resulted from internalization of the 131 Ip67-CD33 complex with subsequent cleavage of 131 I from the antibody and excretion from the marrow space. Of the 9 patients, only 4 had "favorable biodistribution," defined as a higher dose of radiation delivered to the marrow and spleen than to other organs. These 4 patients then received therapeutic doses of 131 Ip67 (110 to 330 mCi) together with cyclophosphamide (120 mg/kg) and total body irradiation (12 Gy) as conditioning regimen for allogeneic bone marrow transplantation. Although the therapy was well tolerated, 3 of the 4 patients eventually relapsed. 16, 31 Because of the short half-life of 131 I-p67 in the marrow and the unfavorable biodistribution in many patients, the investigators have since focused on the 131 I-anti-CD45 radioimmunoconjugate discussed below. 32 90 Y-HuM195 -Compared with other β-particle emitters, 131 I has several disadvantages. First, because of long-ranged γ emissions, patients must be hospitalized and isolated. Second, the long physical half-life of 131 I (8.1 days) delays the time from treatment to stem cell infusion in patients undergoing transplantation. Third, when IgG is labeled with high doses of 131 I, the ability of the antibody to bind to the target antigen is dramatically reduced. This occurs because approximately one third of the tyrosine residues, to which 131 I binds, are in the hypervariable regions of M195 and HuM195. 33 Therefore, multiple infusions of 131 I-M195 or 131 IHuM195 are needed to deliver adequate radiation doses to the marrow for ablation.
90 Y offers several advantages over 131 I for myeloablation. After internalization of antigen-antibody complexes into target cells, radiometals such as 90 Y are better retained within these cells. Furthermore, because 90 Y is a pure β-emitter, large doses can be given safely in the outpatient setting with fewer consequences for medical personnel or patients' families. In a phase I trial at MSKCC, 90 Y-HuM195 was studied in patients with relapsed or refractory AML. Nineteen patients were treated with escalating doses of 90 Y-HuM195 (0.1 to 0.3 mCi/kg). Transient low-grade liver function abnormalities occurred in 11 patients. Myelosuppression lasted 9 to 62 days, and the maximum tolerated dose without stem cell rescue was 0.275 mCi/kg. Biodistribution and dosimetry studies were performed by co-administering 111 In-HuM195. Up to 56 Gy and 75 Gy were delivered to the marrow and spleen, respectively. Thirteen patients had reductions in bone marrow blasts, and 1 patient achieved a complete remission lasting 5 months. All patients treated with 0.3 mCi/kg had hypocellular bone marrow biopsies performed 2 or 4 weeks after treatment, without evidence of leukemia. These results suggest that 90 Y-HuM195 will be useful as conditioning before stem cell transplantation.
14 Clinical trials investigating this agent as part of preparative regimens for autologous and nonmyeloablative allogeneic stem cell transplantation are now underway.
Radiolabeled Anti-CD45 Antibodies CD45 is a tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes. It is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. Unlike CD33, it does not internalize after antibody binding. BC8 is a murine IgG1 anti-CD45 antibody. 17, 18 In a phase I trial at FHCRC, 44 patients with advanced acute leukemia or myelodysplasia received a biodistribution dose of 131 I-BC8. Thirty-seven of the 44 had favorable biodistribution of the radiolabeled antibody. Thirty-four of these patients then received a therapeutic dose of 131 I-BC8 followed by the conditioning regimen of cyclophosphamide (120 mg/kg) plus total body irradiation (12 Gy) before allogeneic or autologous transplant. An estimated radiation dose to the liver of 10.5 Gy was the maximum tolerated dose that could be administered with cyclophosphamide and total body irradiation. Of the 25 patients with AML or MDS, 7 survived disease-free at a median follow up of 65 months after transplantation. Of the 9 patients with ALL, 3 survived disease-free at 19, 54, and 66 months. The estimated maximum tolerated supplemental dose of radiation added by 131 I-BC8 was 24 Gy to the bone marrow and 50 Gy to the spleen. 17 Subsequently, a phase I/II trial of 131 I-BC8 together with busulfan and cyclophosphamide prior to matched related allogeneic transplantation was begun in patients with AML in first remission. Ninety percent of patients had a favorable biodistribution of the radiolabeled antibody. These patients were then treated with therapeutic doses of 131 I-BC8, delivering 3.5 Gy (4 patients) or 5.25 Gy (all subsequent patients) to the liver, half the maximum tolerated dose defined in the phase I study. Toxicities attributable to the 131 I-BC8 were minimal. In an encouraging preliminary report, 18 of 24 patients treated with therapeutic doses were alive and disease-free at a median of 42 months after transplant. [17] [18] [19] These studies indicate that 131 I-BC8 can be administered safely to patients and can increase the dose of radiation delivered to the marrow when given as part of a conditioning regimen before hematopoietic stem cell transplantation.
Radiolabeled Anti-CD66c Antibodies CD66c, also known as nonspecific cross-reacting antigen (NCA), is a glycoprotein expressed on myeloid cells but not on leukemia cells. BW 250/183 is a murine monoclonal IgG1 antibody directed at CD66c. 20 188 Re is a radiometal with a 17-hour half-life. It emits both β and γ radiation, which allows biodistribution and dosimetry studies to be performed easily.
A phase I dosimetry trial showed that administration of 188 Re-BW 250/183 resulted in a favorable biodistribution in 11 of 12 patients, with significant amounts of radiation delivered to the marrow. 20, 21 In a subsequent trial at the Ulm University Hospital in Germany, 22 36 patients with high-risk AML or myelodysplastic syndrome were treated with 188 Re-BW 250/183 prior to hematopoietic cell transplantation. After treatment with radiolabeled antibody, patients received one of three preparative regimens: total body irradiation (12 Gy) plus cyclophosphamide (120 mg/kg), busulfan (12.8 mg/kg) plus cyclophosphamide (120 mg/kg), or total body irradiation (12 Gy) plus thiotepa (10 mg/kg) and cyclophosphamide (120 mg/kg). Antithymocyte globulin was used to prevent graft rejection in patients receiving grafts from unrelated or mismatched related donors. Thirty-one patients received allogeneic grafts (mostly T-cell-depleted), 1 received a syngeneic graft, and 4 received autologous grafts. Favorable biodistribution of 188 Re-BW 250/183 occurred in all patients. The mean therapeutic dose of radiolabeled antibody administered was 11.1 GBq (300 mCi). The median dose delivered to the bone marrow was 14.9 Gy (range 8.1 to 28 Gy). Besides the toxicity normally associated with the conventional preparative regimens, no additional toxicity attributable to the radiolabeled antibody occurred. However, 6 patients developed nephrotoxicity between 6 and 12 months after the transplant. The authors note that nephrotoxicity after bone marrow transplantation may be an effect of radiation. Engraftment occurred in all patients and was not delayed. Disease-free survival was 45% at the median follow-up of 18 months. Disease-free survival was higher in patients undergoing transplantation while in remission (67%) than in those undergoing transplantation while not in remission (31%). Nine of 35 evaluable patients relapsed. Eight patients died from transplant-related toxicity. 22 This study suggests that 188 Re-BW 250/183, similar to 90 Y-HuM195 and 131 I-BC8, may deliver significant doses of radiation to the marrow without excessive toxicity.
Radiolabeled Anti-CD25 Antibodies
The interleukin-2 receptor (IL-2R) consists of at least three IL-2 binding subunits: IL-2Rα (also known as CD25 or Tac), IL-2Rβ, and IL-2Rγ. Normal lymphocytes do not express IL-2Rα. However, in patients with human T-cell leukemia virus I (HTLV-I)-associated adult T-cell leukemia, virtually all of the leukemic cells express 10,000 to 35,000 IL-2Rα receptors per cell. Anti-Tac is a murine MAb that binds to IL-2Rα and prevents its interaction with IL-2. In a phase I/II trial, 18 patients with adult T-cell leukemia were treated with 90 Y-anti-Tac. Nine patients were treated in a phase I dose escalation trial (5 to 15 mCi), and the remaining 9 patients were treated with a uniform dose of 10 mCi. Patients who had a remission were eligible for additional cycles of treatment. Of 16 evaluable patients, 7 had partial remissions (mean duration, 9.2 months), and 2 had complete remissions. Of the 2 patients with complete remissions, 1 patient developed myelodysplasia and died of secondary AML 3 years after receiving 90 Y-anti-Tac. At autopsy, the patient had persistent adult T-cell leukemia present in the skin. The second patient with a complete remission remained without evidence of disease for more than 3 years after the initiation of therapy. Toxicities of 90 Y-anti-Tac included myelosuppression, transient hepatic toxicity, and transient proteinuria. One patient died of unexplained cardiac asystole 23 days after the administration of 90 Y-anti-Tac. Six patients developed human antimouse antibodies. 23 
Radioimmunotherapy With α-Particle Emitters

Preclinical Studies
The high linear energy transfer and short particle path length of α decays offer the potential for selective killing of tumor cells. The specificity and efficacy of targeted α-particle radioimmunotherapy with 212 Bi, 213 Bi, and 211 At have been reported in several experimental models. [34] [35] [36] In one of the first reports suggesting the feasibility of this approach, 212 Bi conjugated to a tumorspecific MAb 103A was used against murine erythroleukemia. Targeting of the construct to neoplastic spleens was seen within 1 hour after injection. When 212 Bi-103A was injected on day 13 after inoculation with leukemia cells, reductions in splenomegaly and the absence of liver metastases were noted. When administered on day 8, no histological evidence of erythroleukemia developed. 37 Similarly, administration of 212 Bi-anti-Tac after inoculation of nude mice bearing CD25-expressing lymphoma cells led to prolonged tumor-free survival and prevented the development of tumors in some animals. Treatment of established tumors, however, failed to produce responses. The explanation for the failure of 212 Bi-anti-Tac to produce responses in established bulky tumors is that most of the 212 Bi had decayed by the time that adequate amounts of radiolabeled antibody were taken up into the tumor cells. 38 213 Bi has a half-life of 45.6 minutes and emits an α− particle of 8 MeV. Additionally, a 440 keV photon emission accompanies 26.5% of 213 Bi decays, allowing detailed biodistribution and dosimetry studies to be performed. The isotope has been prepared from a 225 Ac/ 213 Bi generator and conjugated to HuM195 using the bifunctional chelating agent 2-(4-isothiocyanatobenzyl) diethylenetriamine pentaacetic acid (SCN-CHX-A-DTPA). 39 Intravenous injections of up to 10 mCi/kg of 213 Bi-HuM195 were safe in mice. The application of bismuth-labeled HuM195 in vitro resulted in dosedependent and specific activity-dependent killing of CD33 positive HL60 cells. Approximately 50% of target cells were killed when only two bismuth atoms were bound to the cell surface. 40 
Bi-HuM195
A phase I dose escalation trial was conducted at MSKCC to determine the toxicity, biodistribution, dosimetry, and biological activity of 213 Bi-HuM195. 15 Eighteen patients with relapsed or refractory AML or chronic myelomonocytic leukemia were treated with 0.28 to 1 mCi/kg of 213 Bi-HuM195. Treatment was well tolerated, and dose-limiting toxicity was not observed. Transient grade 1 or 2 liver function abnormalities occurred in 6 patients. Myelosuppression lasting 8 to 34 days was seen in all patients. Gamma camera imaging showed localization of 213 Bi to expected areas of leukemic involvement, including the bone marrow, liver, and spleen, within 5 to 10 minutes after injection. The absorbed dose ratios between these sites and the whole body were 1,000-fold greater than those seen with β-emitting constructs in this antigen system. 41 Thirteen of 15 evaluable patients had reductions in peripheral blood leukemia cells, and 14 of the 18 patients had decreases in the percentage of bone marrow blasts. No complete remissions were observed. Because of the nature of α-particle radiation, complete remission at 30 days after treatment would have required the individual targeting and killing of 99.9% of the leukemia cells. Given that the patients treated on this study had tumor burdens of up to 10 12 cells, each with an average CD33 density of 10,000 per cell, roughly 10 16 leukemic binding sites were available to HuM195. Since approximately 1 in 2,700 molecules of HuM195 carried the radiolabel at the specific activities injected, it was difficult to deliver one to two 213 Bi atoms to every leukemia cell, even if optimal antibody targeting were assumed. Nevertheless, this trial is the first proof-of concept for systemic targeted α-particle immunotherapy in humans and provides the rationale for the continued investigation of this approach in a variety of cancers where minimal residual disease or micrometastatic disease may be present.
More recently, 225 Ac has been conjugated to a variety of MAbs using the bifunctional chelate SCN-DOTA. 225 Ac has a 10-day half-life and decays by α emission through three atoms, each of which also emits an α− particle. In vitro, 225 Ac coupled to internalizing MAbs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at doses 1,000 times less than 213 Bi-containing radioimmunoconjugates. In xenograft models of disseminated human lymphoma and solid prostate carcinoma, single doses at nanocurie levels of tumor-specific constructs prolonged survival and cured a substantial fraction of animals without toxicity. 42 Therefore, in this strategy, 225 Ac-SCN-DOTA serves as an atomic nano-generator that delivers a cascade of four α-particles to the inside of a cancer cell by an internalizing antibody. A phase I trial of 225 Ac-HuM195 in advanced myeloid leukemias is planned.
Conclusions
Radioimmunotherapy for leukemia is a promising strategy designed to increase the efficacy of native MAbs, decrease the toxicity of therapy by targeting radiation to specific cell types or organ systems, and ultimately improve the long-term outcome for patients with leukemia. Radioimmunotherapy with β-particle emitters may be most effective for the treatment of bulky disease or as part of a conditioning regimen for hematopoietic stem cell transplantation, whereas radioimmunotherapy with α-particle emitters may be better suited for the treatment of small-volume or minimal residual disease. The phase I and phase II studies described above have demonstrated that radiolabeled antibodies have activity in refractory leukemias, can be administered safely, and can increase the dose of radiation delivered to the marrow when given as part of a conditioning regimen before hematopoietic stem cell transplantation. Whether or not radiolabeled antibodies improve outcome compared with standard chemotherapy agents or conditioning regimens remains to be demonstrated by randomized phase III clinical trials. Future research must also define optimal combinations of MAb and radioisotope in various clinical settings.
